LRMR Larimar Therapeutics
- 9.240
- -0.280-2.94%
Larimar Therapeutics News
Buy Rating for Larimar Therapeutics Backed by Promising Gene Therapy Advances for Friedreich's Ataxia
Larimar Therapeutics Analyst Ratings
Buy Rating Affirmed for Larimar Therapeutics as FDA Accelerates Nomlabofusp's Path in START Pilot Program
Buy Rating on Larimar Therapeutics: Navigating FDA Approval With Promising FA Treatment
Larimar Therapeutics Analyst Ratings
Larimar Therapeutics Analyst Ratings
Buy Rating Reaffirmed for Larimar Therapeutics Post FDA Clinical Hold Lift and Positive Drug Trial Trajectory
Optimistic Buy Rating for Larimar Therapeutics Backed by Positive Phase 2 Results and Strategic FDA Discussions
Buy Rating for Larimar Therapeutics Backed by Strong Clinical and Financial Outlook
Buy Rating Affirmed for Larimar Therapeutics Amid Promising Phase II Data and Strategic OLE Study for FA Treatment
Larimar Therapeutics Analyst Ratings
Buy Rating Justified: Larimar Therapeutics' Advancements Towards FDA Approval for FA Drug Nomlabofusp
Larimar Therapeutics Analyst Ratings
JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
Larimar Therapeutics Analyst Ratings
Buy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich's Ataxia
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)
Buy Rating Affirmed: Larimar Therapeutics' Nomlabofusp Shows Potential in Friedreich's Ataxia Treatment
Larimar Therapeutics Analyst Ratings
Buy Rating Affirmed: Larimar Therapeutics' Promising Drug Advances on Regulatory and Efficacy Fronts
Analysis
Price Target
No Data
